FSD Pharma Wins Court Judgment Against Former CEO, Dr. Raza Bokhari
FSD Pharma Wins Court Judgment Against Former CEO, Dr. Raza Bokhari
FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces that on June 27, 2024, the United States District Court for the Eastern District of Pennsylvania confirmed FSD Pharma, Inc.'s motion for entry of judgment is granted and judgment is entered in favour of FSD Pharma and against Dr. Raza Bokhari as follows:
FSD Pharma Inc.（納斯達克：HUGE）（CSE：HUGE）（FRA：0K9A）（“FSD Pharma”），一家專注於打造創新資產和生物科技解決方案來解決影響全球數百萬人的疾病的生物製藥公司，今天宣佈，2024年6月27日，美國賓夕法尼亞東區聯邦地區法院確認FSD Pharma，Inc.的判決書入場，判決書支持FSD Pharma針對拉扎·博卡里博士的申請，並判決如下:
- USD $147,301.04, plus interest at a rate of 4% per annum from November 9, 2022 until the date the Judgment is satisfied.
- CAD $31,912.55, plus interest at a rate of 4% per annum from November 9, 2022 until the date the Judgment is satisfied.
- CAD $15,000.00, plus interest at a rate of 4% per annum from March 1, 2023 until the date the Judgment is satisfied.
- CAD $2,814,229.15, plus interest at a rate of 6% per annum from May 7, 2023 until the date the Judgment is satisfied.
- 147,301.04美元，再加上自2022年11月9日起按年利率4％計算的利息，直至判決生效之日。
- 31,912.55加元，再加上自2022年11月9日起按年利率4％計算的利息，直至判決生效之日。
- 15,000.00加元，再加上自2023年3月1日起按年利率4％計算的利息，直至判決生效之日。
- 2,814,229.15加元，再加上自2023年5月7日起按年利率6%計算的利息，直至判決生效之日。
In July 2021, FSD's board of directors terminated Dr. Raza Bokhari, its former CEO. Dr. Raza Bokhari filed an arbitration challenging this termination in Ontario, Canada. After years of litigation and an eight-day evidentiary hearing, the Arbitrator ruled against Dr. Raza Bokhari and issued three awards against Dr. Raza Bokhari in favor of FSD, including an award for damages and awards for FSD's fees and costs incurred in the arbitration.
2021年7月，FSD的董事會終止了前CEO拉扎·博卡里博士的職務。拉扎·博卡里博士在加拿大安大略省提起仲裁挑戰此終止。經過多年的訴訟和爲期八天的證據聽證會，仲裁員裁定駁回拉扎·博卡里博士的訴求，並頒發了三項裁決，其中包括賠償金和FSD在仲裁期間支出的費用和成本的賠償。
FSD's Petition to Confirm the Arbitration Awards was filed May 29, 2024 in the United States District Court for the Eastern District of Pennsylvania under the Convention on the Recognition and Enforcement of Foreign Arbitral Awards, June 10, 1958, 21 U.S.T. 2517, 330 U.N.T.S. 3 (the "New York Convention"). In its opinion granting FSD's Petition, the District Court found that Dr. Raza Bokhari did not offer any valid basis under the New York Convention for the Court to deny enforcement of the arbitration awards against him.
FSD的仲裁裁決確認請求於2024年5月29日根據1958年6月10日《外國仲裁裁決承認和執行公約》（“紐約公約”）在美國賓夕法尼亞東區聯邦地區法院提出。在支持FSD的請願書的裁決意見中，地區法院認爲，拉薩·博卡里博士未提供任何有效的紐約公約依據，使法院拒絕執行對他的仲裁裁決。
FSD will pursue all means possible to collect from Dr. Raza Bokhari, current chairman and CEO of Medicus Pharma Ltd.
FSD將採取一切可能手段從Medicus Pharma Ltd的現任主席兼CEO拉扎·博卡里博士收取款項。
譯文內容由第三人軟體翻譯。